Invokana Lawyers Reviewing Cases Nationwide
Invokana (canagliflozin) is a new type of diabetes drug introduced by Johnson & Johnson in March 2013, which rapidly grew to become a blockbuster treatment amid aggressive marketing. However, it now appears that the drug maker may have withheld important information about the potential risks users may face from Invokana side effects.
Due to a failure to warn consumers and the medical community, financial compensation may be available through an Invokana lawsuit for individuals who have suffered:
- Diabetic Ketoacidosis
- Leg or Foot Amputation
- Kidney Failure
- Heart Attack
- Wrongful Death
The product liability lawyers at Saiontz & Kirk, P.A. provide confidential case evaluations to help determine if you or a loved one may have an Invokana injury case.
Call 1-800-522-0102 or Request a Free Case Review.
Invokana was the first member of a new class of diabetes drugs introduced in the U.S., known as sodium-glucose co-transporter 2 (SGLT2) inhibitors.
The lawyers at Saiontz & Kirk are investigating Invokana lawsuits for individuals throughout the United States. As a result of the drug maker’s failure to adequately warn, financial compensation may be available.
The medication works by inhibiting some normal kidney functions, to increase the amount of sugar excreted in the urine. This was designed to increase glucose production and lower blood glucose levels among diabetics. However, it may cause users to experience serious and potentially life-threatening health problems.
Although information about the potential injury risks with Invokana should have been known or suspected before the medication was introduced, lawsuits pursued on behalf of former users will allege that Johnson & Johnson failed to properly study the medication or adequately warn about serious side effects.
During the first year the medication was on the market, hundreds of reports involving Invokana problems were submitted to federal drug regulators, including reports of:
- Kidney Failure
- Kidney Impairment
- Kidney Stones
- Urinary Tract Infections
- Abnormal Weight Loss
- Hypersensitivity Reactions
The first public disclosure about the potential risk of problems with Invokana came in early 2015, when the FDA issued a drug safety communication about a large number of adverse event reports involving users hospitalized after accumulating high levels of acid in the blood; which is a serious medical condition known as ketoacidosis or ketosis.
In December 2015, the FDA announced that new Invokana warnings will be added to the drug label, indicating that patients should stop using the drug immediately and seek medical assistance if they began experiencing signs of diabetic ketoacidosis side effects, such as:
- Difficulty Breathing
- Nausea or Vomiting
- Abdominal Pain
- Confusion, Fatigue or Sleepiness
The FDA highlighted at least 73 adverse event reports received involving ketoacidosis with Invokana or other similar diabetes drugs. Each of the cases resulted in hospitalization or emergency room treatment.
Information about the risk of amputations on Invokana and Invokamet was first disclosed in May 2016, when the FDA issued another drug safety communication about early results from a clinical trial, which identified a large number of amputated legs and feet, particularly involving the toes.
About a year later, the FDA announced that new label information about the link between Invokana and amputations would be placed prominently in a “black box”, which is the strongest warning that can be required for a prescription medication.
The agency determined that nearly 6 out of every 1,000 patients that take Invokana or Invokamet may require an amputation, which is double the risk seen among diabetics given a placebo. In addition, similar amputation problems were not seen among users of other competing diabetes drugs.
Concerns about the kidney risks with Invokana began to emerge shortly after the drug hit the market, with higher-than-expected numbers of adverse event reports submitted by users nationwide. Experts suggest that the manufacturer knew or should have known this would be a problem, since the drug works in a unique way by inhibiting certain normal kidney functions.
Warning label updates have been required for a number of kidney problems, providing new information for consumers and doctors about the risk of urinary tract infections, kidney infections and acute kidney injury.
In June 2016, the FDA announced that Invokana kidney warning were being strengthened to highlight the importance of monitoring for signs or symptoms of issues where the kidneys may suddenly stop working, causing dangerous levels of waste to build up in the body.
For many users, these warnings and label updates came too late, or resulted in inaccurate and inadequate information being provided to users. If the full extent of the Invokana risks were known, many individuals left with severe and life-altering injuries may have elected to use a different diabetes treatment.
Allegations To Be Raised in Invokana Lawsuits
- Failure to Study Invokana Health Risks;
- Failure to Warn about Risk of Ketoacidosis, Heart Attacks, Amputations, Strokes or Kidney Failure from Invokana;
- Misrepresenting the Safety of Invokana;
- Failure to Issue an Invokana Recall
Invokana Class Action Lawyers
Individuals who have been hospitalized due to ketoacidosis, required a foot or leg amputation, been diagnosed with kidney failure or suffered a heart attack may be entitled to financial compensation through an Invokana class action lawsuit or individual injury claim.
Similar claims are being reviewed for users of other SGLT2 inhibitor diabetes drugs, including Invokamet lawsuits, Farxiga lawsuits, Xigduo XR lawsuits, Jardiance lawsuits and Glyxambi lawsuits. The makers of Invokana and these other new-generation diabetes drugs appear to have placed their desire for profits before consumer safety, by rushing the medications to the market.
As a result of the apparent decision to place the desire for profits before consumers safety, Invokana settlements may be available.
Free consultations and case evaluations are provided by the Invokana lawyers at Saiontz & Kirk, P.A. to help individuals and families determine whether they may be eligible to pursue a case. All lawsuits are pursued under a contingency fee agreement, which means that there are no out-of-pocket expenses to hire our Invokana law firm and we only receive attorney fees or expenses if a recovery is obtained.